4th Annual Gene Therapy Analytical Development Summit 2022

The past twelve months have culminated in an unprecedented level of excitement, investment, and clinical progress within the gene therapy field. As the field strives to strike a delicate balance between safety and efficacy, in the context of increased regulatory scrutiny and safety challenges, attending the 4th Annual Gene Therapy Analytical Development as an analytical scientist has never been so important.

This year's summit returns in-person to Boston to reunite 300+ analytical experts in innovative biotech, pharma and academia to continue to develop resilient, long-lasting and robust analytical tools to enhance the safety, quality and efficacy of gene therapy products.  

Whether you are focusing on specific characterization methods, enhancing your genome sequencing, advancing your understanding of full and partial particles, or advancing your early-stage bioassays, with 4 tracks, 8 pre-conference workshops and a post-conference focus day, the 4th Gene Therapy Analytical Development Summit will encompass all aspects of analytical development, giving you the chance to address and overcome challenges.

If you work in quality control, quality assurance, or process development - we've listened and we've answered. This year's agenda includes a novel track designed for quality control and process development groups working in gene therapy. Talks include enhancing the knowledge transfer between departments, bridging between analytical methods with regards to QC/PD, and enhancing in-process development support.

Whether you're working with AAV, non-viral vectors or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.

URLs:
Tickets: https://go.evvnt.com/1259027-2?pid=185
Brochure: https://go.evvnt.com/1259027-3?pid=185

Prices:
2 Day Conference Only - Drug Developer: USD 2999.00,
2 Day Conference + Workshop Day OR Discussion Day - Drug Developer: USD 3997.00,
FULL ACCESS PASS: 2 Day Conference + Workshop Day AND Discussion Day - Drug Developer: USD 4995.00,
2 Day Conference Only - Standard : USD 3999.00,
2 Day Conference + Workshop Day OR Discussion Day - Standard : USD 4997.00,
FULL ACCESS PASS: 2 Day Conference + Workshop Day AND Discussion Day - Standard : USD 5995.00

Speakers: Adebowale Shoroye, Scientist, Biogen, Alexander Wong, Principal Research Associate, Sanofi Genzyme, Andrea Hamilton, Associate Director, Quality Control, Gyroscope Therapeutics, Andrea Sobjack, Associate Director, Janssen Research and Development, Anthony Leyme, Principal Scientist, Analytical Development, Elevate Bio, Bernice Yeung, Senior Director, Head of Analytical Development, Biogen, Bryan Troxwell, Director, Stride Bio, Connie Tsai Associate Director, Analytical Development, Novartis Gene Therapies, Courtney Sloan, Principal Scientist and Group Leader, Pfizer, Craig Jerome, Analytical Development/ Quality Control Associate, AGTC, Cullen Mason, Associate Director, Head of Gene Therapy and Assay Development, Biogen, David Dobnik, Senior Research Associate, National Insitute of Biology, Debashree Basu, Senior Scientist, Analytical Development, Ultragenyx, Dwayne Neal, Senior Director, Analytical Sciences and Technology, AVROBIO, Elena Peletskaya, Director, Gene Delivery Analytics, BMS, Felipe Gazos-Lopes, Associate Director for Analytical Development, Tessera Therapeutics, Gary Li Director, Quality Control, Capsida Inc., Graham Whyteside, Senior Director, Platform Development, AskBio, Huimin Tao, Principal Scientist, Analytical Development, Novartis Gene Therapies, Ilya Shestopalov, Senior Director, Analytical Product Lead, bluebird bio, Jarrod Dean, Associate Director, NGS Leader, Genomics Medicine Unit CMC, Sanofi, Jessica Gee, Research Associate, Sangamo Therapeutics, Jing Zhu Director, Process and Analytical Development, RVAC Medicines, Joseph Schroer, Engineer, Genentech, Kamila Pytel, Associate Director, CMC Analytical Development, Gyroscope Therapeutics, Kinnari Patel, President and COO, Rocket Pharmaceuticals, Lamine Bouakaz, Global Head Cell and Gene Product Supply, Santen, Marina Feschenko, Senior Director, Analytical Development, Intergalactic Therapeutics, Matthew Blackburn, Senior Scientist, Assay Development, Abeona Therapeutics, Matthew Sampson, Manager, QC Gene Therapy Analytical Technology, Biogen, Monica Terraro, Senior Scientist, CSL Behring, Nathalie Clement, Consultant, Unicorn Consultants, Pavlina Wolf, Senior Scientist, Editas Medicine, Peter Clarner, Gene Therapy Accelerator and Unit Scientist, Biogen, Ronald Toth Senior Scientist, Characterization  Sanofi, Ruth Frenkel, Scientist II, Analytical Development, Biogen, Santoshkumar Khatwani, Director, Analytical Development, Sangamo Therapeutics, Sarah Dickerson, Senior Scientist, Process Analytics, Umoja Biopharma, Scott Burger, Principal, Advanced Cell and Gene Therapy, Srihariraju Mulagapati, Senior Scientist, AstraZeneca, Susan Sleep, Director, Assay Development, AGTC, Tom Colace, Director, LNP Process Development, Tessera Therapeutics, Tushar Patel, Director, Analytical Development, Vedere Bio II, Wei Zhang, Associate Director, Analytical Development, Ultragenyx Pharmaceuticals, Wei-Chiang, Chen BioProcess Analytics, Genomic Medicine Unit, Sanofi, William Werner, Senior Director, Analytical Assay Development, Audentes Therapeutics, Xiaoying Jin, Head of GMU BioAnalytical Characterization, Sanofi, Yiling Bi, Scientist III, Analytical Development, Sangamo Therapeutics, Judit Bartalis, Senior Scientist, Novartis Gene Therapies, Zhijie Wu, Scientist, Regeneron, Sachin Thakkar, Staff Scientist, Bayor College of Medicine, Stuart Nelson, Senior Analytical Scientist, Prevail Therapeutics